European or international
Funding: CAPES - COFECUB (Comité Français d'Evaluation de la Coopréation Universitaire et Scientifique avec le Brésil)
Coordinator: Cédrick Bonnet
Funding: PHC Aurora - Campus France
Coordinator: Bilge Sayim & Pr Jonas R. Kunst, University of Oslo
Funding: PHC BOSPHORE - Campus France
Coordinator: Bilge Sayim
"Information compression by the visual brain and the neural signature of redundancy masking" with Sabanci University, Istanbul
Funding: 3 universités brésiliennes (USP, UNESP, UNICAMP) et le Consulat Général de France à Sao Paulo
Coordinator: Cédrick Bonnet
Partners in lab: Delphine Grynberg et Christelle Duprez
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization.
FAIR’s objectives are to:
• develop nebulization modalities for optimal airway targeting and rapid action at the infection site
• demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibioticresistant pneumonia
• identify host immune factors required for the gain of protection with systems biology
• implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation
• assess nebulized flagellin’s safety in a Phase I clinical trial.
• analyze the acceptability and economic relevance of the therapy
• identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts.
Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.
Funding: PHC Maimonide, Campus France
Coordinator: Yann Coello
France : Mme Bartolo Angela*, Professeur
M. Coello Yann*, Professeur
M. To be recruited To be recruited*, PhD
Israël : M. Fishbain Barak*, Assistant professor
Mme Givon-Benjo Nur*, Phd
Mme Okon-Singer Hadas*, Associated professor
Funding: Interreg 2 Seas Mers Zeeën
Partners in lab: Emilie Wawrziczny et Pascal Antoine
Funding: Interreg 2 Mers
Partners: Pascal Antoine et Mohamad El Haj (University of Nantes)